Perspective Therapeutics, Inc. Overview
Pro stress-test →Perspective Therapeutics develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. This represents a focused approach to radiopharmaceutical oncology with multiple candidates in clinical development.
Strategic Profile
Pro stress-test →The company's lead candidate VMT-a-NET is in Phase 1/2a clinical trials for neuroendocrine tumors, while VMT01 targets melanoma, PSV359 targets fibroblast activation protein alpha, and PSV4XX targets prostate-specific membrane antigen. Perspective has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab in melanoma patients.
Competitive Landscape
Pro stress-test →Perspective competes in the radiopharmaceutical oncology space with candidates targeting multiple tumor types including neuroendocrine tumors (competing with beta-emitting therapies like Lutathera), melanoma, FAP-positive cancers, and PSMA-expressing prostate cancer. The company's alpha-therapy approach differentiation focuses on precision targeting and reduced normal tissue toxicity compared to traditional beta emitters.
Industry Context
Perspective Therapeutics, Inc. operates in Radiopharmaceutical Oncology / Targeted Alpha Therapy.
Key facts
Founded: 2004 · Headquarters: Seattle, Washington · Revenue: $1.45M (2024) · Market cap: $0.614B